Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

NCT03497845
completedphase_1

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

NCT02251288
completedphase_1

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

NCT02624219
completedphase_1

H5N1 Mix and Match With MF59

NCT01317745
completedphase_2

Recombinant CMV gB Vaccine in Postpartum Women

NCT00125502
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03497845Phase 2

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Completed
NCT02251288Phase 1

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Completed
NCT02624219Phase 1

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

Completed
NCT01317745Phase 1

H5N1 Mix and Match With MF59

Completed
NCT00125502Phase 2

Recombinant CMV gB Vaccine in Postpartum Women

Completed
NCT00133471Phase 1

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6